By Lea Gigon | Project Leader
Sarcomas are rare but aggressive cancers that arise in supportive and connective tissues such as muscles, bones, fat, or tendons. “You can think of this tissue as the body’s framework,” explains Dr. Melita Irving. “When cells within this framework begin to divide uncontrollably, sarcomas develop." While rare in adults, sarcomas account for approximately 20 percent of all solid malignant tumors in children. Sarcomas are frequently caused by sudden genetic alterations known as gene fusions. “Children are particularly vulnerable because their cells divide rapidly during growth,” explains Dr. Antonia Digklia. “This increases the likelihood of such genetic errors.”
Current treatment options—including chemotherapy and targeted drugs—are often insufficient. “Many children experience relapses, and the side effects of treatment can be severe,” says Dr. Melita Irving. Even modern immunotherapies, such as checkpoint inhibitors, have so far benefited only a small proportion of patients with sarcomas.
At the Centre hospitalier universitaire vaudois (CHUV) in Lausanne, the two scientists are focusing on advancing adoptive cell therapy. In this approach, the body’s own immune cells—known as T cells—are genetically modified to recognize and specifically destroy cancer cells. “We are developing specialized receptors that guide T cells directly to sarcoma cells,” explains clinical researcher Digklia. In addition, the T cells are engineered to remain active for longer periods and to function safely within the challenging tumor environment. “Our goal is a therapy that is powerful enough to defeat the cancer, yet gentle enough to allow children to live normal lives.”
The greatest challenge lies in balancing effectiveness and safety. Nevertheless, the potential is significant. “We hope that our research will pave the way for new, effective immunotherapies—not only for sarcomas, but also for other rare solid tumors,” the researchers say with confidence.
Your donations are making a lasting impact. Discover how Dr. Irving and her research team are finding a a new path of hope for children with sarcomas, thanks to the support of generous donors like you.
By Lea Gigon | Project Leader
By Peggy Janich | Project Leader
Project reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you can receive an email when this project posts a report. You can also subscribe for reports without donating.
Support this important cause by creating a personalized fundraising page.
Start a Fundraiser